Switch Therapeutics
Saumya Das is currently a Professor of Medicine at Harvard Medical School and holds the position of Associate Professor. Since July 2015, Saumya Das has served as Co-Founder, Senior Scientific Advisor, and Consultant at Long QT Therapeutics, while also co-founding Switch Therapeutics in April 2020. Additionally, Saumya Das is a faculty member at Massachusetts General Hospital and has been the Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Mass General Physicians Organization since May 2016. Previously, Saumya Das co-founded Dyrnamix Inc. from March 2017 to April 2020. Educationally, Saumya Das earned an M.D. and Ph.D. in Neurobiology and Neurosciences from Harvard Medical School between 1991 and 2000, and a Bachelor of Arts in Biology from Harvard University from 1987 to 1991.
This person is not in any teams
This person is not in any offices
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.